The incidence of hypochondroplasia is not known, but it has been estimated to be about as common as achondroplasia, which is seen in around 1 in 15,000 to 40,000 births. BioMarin has said that ...

Achondroplasia is a type of dwarfism that affects the growth in children, leading to a short stature or small size. Achondroplasia is a rare genetic condition that affects one in every 15,000 to ...

BioMarin Pharmaceutical’s Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in Europe and the U.S ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

BioMarin reported a strong quarter, and Voxzogo still has ample room to grow from here, both in terms of greater penetration of the achondroplasia market and in expansion indications longer-term ...

Achondroplasia dwarfism is the most common type of skeletal dysplasia. It’s the cause for 90% of cases of markedly short stature in people. Achondroplasia targets bone growth in the arms and legs.

BioMarin reported noteworthy regulatory advancements, including guidance on achondroplasia screening and extending Voxzogo availability to 47 countries, with ambitions to reach 60 markets by 2027.

BioMarin Pharmaceutical BMRN is scheduled ... Since its commercial launch in 2021, sales of the achondroplasia drug Voxzogo have been experiencing rapid uptake, driven by strong prescription ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.